Cidara's Once-Weekly Antifungal Gets Phase III Boost From Mundipharma
Mundipharma is to provide financial support and development expertise for Cidara’s Phase III clinical studies of its once-weekly echinocandin antifungal for serious infections, in return for ex-US and ex-Japanese marketing rights.
You may also be interested in...
Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections
Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Cidara’s Rezafungin Hits Approvable Endpoints For Candida Infections
Phase III data for the novel echinocandin demonstrated non-inferiority to caspofungin for all-cause mortality at day 30 and for global cure at day 14. Regulatory filings are planned for 2022.